摘要
目的:观察仙灵骨葆胶囊联合地舒单抗对老年骨质疏松性胸腰椎压缩性骨折术后骨密度及炎症因子水平的影响。方法:将120例老年骨质疏松性胸腰椎压缩性骨折术后患者按照随机数字表法分为观察组和对照组,每组各60例。所有患者均接受常规治疗,对照组在常规治疗的基础上给予地舒单抗皮下注射治疗,观察组在对照组治疗的基础上合用仙灵骨葆胶囊。比较两组患者的临床疗效、不良反应发生率及治疗前后中医证候积分、骨密度、Cobb角、Oswestry功能障碍指数(Oswestry disability index,ODI)、炎症因子[白细胞介素(interleukin,IL)-17、IL-6、IL-1β]水平。结果:对照组有效率为78.33%,观察组有效率为91.67%,两组患者有效率比较,差异有统计学意义(P<0.05)。两组患者治疗后中医证候积分、Cobb角及ODI低于本组治疗前,骨密度高于本组治疗前,且治疗后组间比较,差异均有统计学意义(P<0.05),两组患者治疗后IL-17、IL-6及IL-1β水平低于本组治疗前,且治疗后观察组低于对照组,差异均有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:仙灵骨葆胶囊联合地舒单抗能够显著提高老年骨质疏松性胸腰椎压缩性骨折术后患者的骨密度,减轻炎症反应,提高生活质量,并有效缓解中医证候。
Objective:To observe the effects of Xianling Gubao Capsules combined with Denosumab on bone mineral density(BMD)and inflammatory factor levels in elderly patients with osteoporotic thoracolumbar compression fracture after surgery.Methods:A total of 120 elderly patients with osteoporotic thoracolumbar compression fracture after surgery were divided into the observation group and the control group according to the random number table method,with 60 cases in each group.All patients received routine treatment.The control group was additionally treated with subcutaneous Denosumab based on the routine treatment,while the observation group received Xianling Gubao Capsules combined with the control group′s regimen.The clinical efficacy,incidence of adverse reactions,changes in TCM syndrome scores,BMD,Cobb angle,Oswestry Disability Index(ODI),and levels of inflammatory factors[including interleukin(IL)-17,IL-6,IL-1β]before and after treatment were compared between the two groups.Results:The effective rate of the control group was 78.33%,and that of the observation group was 91.67%.The difference between the two groups showed a statistically significant difference(P<0.05).After treatment,the levels of IL-17,IL-6 and IL-1βin both groups were lower than those before treatment,and the levels in the observation group were lower than those in the control group,with statistically significant differences(P<0.05).There was no statistically significant difference in the incidence of adverse development between the two groups(P>0.05).The TCM syndrome scores,cobb angle,and ODI in both groups were lower than those before treatment in their respective groups,while BMD was higher than that before treatment in their respective groups.Moreover,all the differences between the two groups after treatment were statistically significant(P<0.05).Conclusion:Xianling Gubao Capsules combined with Denosumab can significantly increase BMD,reduce inflammatory reactions,improve quality of life,and effectively alleviate TCM syndromes in elderly patients with osteoporotic thoracolumbar compression fracture after surgery.
作者
胡伟
张斌
陶志强
杨盼盼
谈荣珍
胡俊
朱莹
HU Wei;ZHANG Bin;TAO Zhiqiang;YANG Panpan;TAN Rongzhen;HU Jun;ZHU Ying(Nanchang Hongdu Hospital of Traditional Chinese Medicine,Nanchang,Jiangxi,China,330000)
出处
《河南中医》
2025年第8期1269-1273,共5页
Henan Traditional Chinese Medicine
基金
江西省中医药管理局科技计划项目(2023B0035,2020A0268)
江西省卫生健康委员会科技计划项目(202311307)。
关键词
骨质疏松性胸腰椎压缩性骨折
仙灵骨葆胶囊
地舒单抗
骨密度
炎症因子
thoracolumbar compression fracture
Xianling Gubao Capsules
Denosumab
bone mineral density(BMD)
inflammatory factors
